| Company/Division name | Fujifilm Irvine Scientific |
| Parent company | FUJIFILM Holdings Corporation |
| Type of work | Manufacturing |
| If manufacturing, is the company an OEM? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 100 |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2023 |
| Domestically, the work will be done: | In-house |
| $/year of sales of reshored product or service: | 188 |
| Country(ies) from which reshored: | Japan |
| City reshored to: | Research Triangle Park |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Cell cultures |
| What non-domestic negative factors made offshoring less attractive? | Intellectual property risk, Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Government Incentives, Higher productivity, Proximity to customers/market |
